FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Vireo Growth's Free Cash Flow for the
three
months ended in Mar. 2026 was €0.5 Mil. Vireo Growth's Revenue for the
three
months ended in Mar. 2026 was €91.9 Mil. Therefore, Vireo Growth's FCF Margin % for the quarter that ended in Mar. 2026 was 0.56%.
The historical rank and industry rank for Vireo Growth's FCF Margin % or its related term are showing as below:
FRA:K95'
s FCF Margin % Range Over the Past 10 Years
Min: -118.98 Med: -31.67 Max: -5.98
Current: -5.98
During the past 13 years, the highest FCF Margin % of Vireo Growth was -5.98%. The lowest was -118.98%. And the median was -31.67%.
FRA:K95's FCF Margin % is ranked worse than 68.27% of 958
companies
in the Drug Manufacturers industry
Industry Median: 2.51
vs FRA:K95: -5.98
Vireo Growth FCF Margin % Related Terms
Vireo Growth FCF Margin % Historical Data
* Premium members only.
The historical data trend for Vireo Growth's FCF Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Vireo Growth's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vireo Growth FCF Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Vireo Growth's FCF Margin % distribution charts can be found below:
* The bar in red indicates where Vireo Growth's FCF Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vireo Growth (FRA:K95) has a FCF Margin % of 0.56% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Vireo Growth and its competitors. According to the industry distribution chart, Vireo Growth ranks #654 out of 958 companies in the Drug Manufacturers industry, placing it in the top 68.3%.
Is Vireo Growth's FCF Margin % too high?
Vireo Growth's current FCF Margin % is 0.56%. The Drug Manufacturers industry median FCF Margin % is 2.51. Vireo Growth's value of 0.56% is 77.7% below this industry median. Based on the distribution chart, Vireo Growth ranks #654 out of 958 companies in the Drug Manufacturers industry, which is below the industry midpoint. Overall, Vireo Growth has a GF Score™ of 44/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Vireo Growth's FCF Margin % compare to ZTS?
According to the Drug Manufacturers industry distribution chart, Vireo Growth ranks #654 out of 958 companies for FCF Margin %. This places Vireo Growth in the lower half of its industry. The industry median FCF Margin % is 2.51. Vireo Growth's value of 0.56% is 77.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Drug Manufacturers company?
The median FCF Margin % among Drug Manufacturers companies is 2.51, based on 958 companies in the industry. Companies in the top quartile (top 25%) have a FCF Margin % significantly above this median, while those in the bottom quartile fall well below. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vireo Growth's current FCF Margin % of 0.56% is 77.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Vireo Growth and its competitors. For the Drug Manufacturers industry, the median FCF Margin % is 2.51 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vireo Growth's current FCF Margin % is 0.56%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vireo Growth stock overvalued right now?
Based on GuruFocus' analysis, Vireo Growth (FRA:K95) is currently considered Modestly Overvalued. The stock's GF Value™ is €7.54, compared to a current price of €8.42 — trading 11.7% above its estimated fair value. The current FCF Margin % is 0.56% and 77.7% below the Drug Manufacturers industry median of 2.51. Vireo Growth's overall GF Score™ is 44/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Vireo Growth (FRA:K95), the current FCF Margin % is 0.56% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vireo Growth (FRA:K95) Overvalued in 2026?
Based on GuruFocus' analysis, Vireo Growth stock appears to be overvalued.
The current stock price of €8.42 is trading 11.7% above its estimated GF Value™ of €7.54.
GuruFocus considers Vireo Growth to be Modestly Overvalued.
Key valuation signals for FRA:K95:
FCF Margin %: 0.56%
GF Value™: €7.54 vs. price of €8.42 (11.7% above fair value)
Industry Position: 77.7% below the Drug Manufacturers median (#654 of 958)
No single metric tells the full story. See the FRA:K95 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vireo Growth Incis a cannabis company whose mission is to provide safe access, quality products and value to its customers while supporting its local communities through active participation and restorative justice programs. The Company is evolving with the industry and is in the midst of a transformation to being significantly more customer-centric across its operations, which include cultivation, manufacturing, wholesale and retail business lines. The company operates in one single segment.
44GF Score
Get the complete analysis for FRA:K95
FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:K95 has been successfully added to your 
